We sought to examine the relationship between high-density lipoprotein cholesterol (HDL-C) levels and the risk of the development of cancer in large randomized controlled trials (RCTs) of lipid-altering interventions.
The relationship between serum cholesterol levels and the risk of cancer in humans is an area of considerable research and debate, especially in the current era of intensive lipidmodifying therapy and more aggressive cholesterol goals to reduce the risk of cardiovascular disease. To date, the literature on cholesterol and cancer has focused predominantly on total serum cholesterol, demonstrating an inverse relationship between serum cholesterol levels and incident cancer (1) . More recently, we reported that serum levels of low-density lipoprotein cholesterol (LDL-C) are significantly and inversely related to the rates of incident cancer in large randomized controlled trials (RCTs) of hydroxymethylglutaryl coenzyme A reductase inhibitors (statins), such that lower levels of LDL-C are associated with higher rates of incident cancer (2) .
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High-density lipoprotein cholesterol (HDL-C) contributes importantly to cardiovascular disease risk, independent of the effects of LDL-C, with a significant inverse relationship between HDL-C levels and the risk of cardiovascular disease (3) (4) (5) (6) (7) . However, very little is known about whether there is a relationship between HDL-C levels and cancer risk. Only a small number of studies have explored the association of HDL-C and cancer, and these have produced mixed results (8 -11) . To date, there is no systematic analysis examining the relationship of HDL-C levels and the risk of incident cancer. In the current study, we took advantage of the numerous large-scale trials of lipidmodifying therapy to examine the relationship between HDL-C levels and the risk of developing cancer.
Methods

Trial inclusion.
A MEDLINE search identified lipid intervention RCTs, published up to September 2009 in the English literature, with at least 1,000 person-years of follow-up. To be eligible, trials had to report both baseline HDL-C and rates of incident cancer. The electronic search strategy included the following terms: cancer, neoplasm, HDL-C, fibrate, niacin, hydroxymethylglutaryl coenzyme A reductase inhibitor, statin, lovastatin, pravastatin, simvastatin, atorvastatin, cerivastatin, fluvastatin, and rosuvastatin. Citations were limited using the terms "human," "English language," and "randomized controlled trial." Additionally, a manual review of the reference lists of eligible trials was performed to ensure that all appropriate studies were included. Data extraction. All citations were screened at the abstract level. Full articles of eligible trials were independently reviewed by 2 investigators (H.J. and A.A.A.-A.), and data directly extracted into electronic data tables. For each eligible study, the following variables were extracted from the published article: the intervention used and the dose; the number of patients in the intervention and control arms; duration of follow-up; baseline and on-treatment serum HDL-C, LDL-C, total cholesterol, and triglyceride levels; and the number of patients with newly diagnosed cancer during the follow-up period. In addition, for each trial arm, age, sex, diabetes, smoking status, and body mass index (BMI) were recorded at baseline. Nonmelanoma skin cancers were not consistently recorded in all trials and were therefore not included in the present analysis. Person-years of follow-up for each study arm were calculated by multiplying the reported follow-up in years by the number of subjects in each arm. The number of incident cancers that were included in the analysis was taken from the values reported as defined in each individual study. Cancer rates were expressed as number of incident cancers per 1,000 patient-years of follow-up for the study arm of interest. Primary and secondary analyses. Our pre-specified primary analysis examined the association between baseline HDL-C levels and incident cancer risk. Each trial arm is considered a separate observation, and intervention and control arms are included together in the analysis. We previously showed in a similar dataset that statin use is not associated with cancer risk (2) . The relationship between baseline HDL-C levels and cancer risk was assessed using random-effects meta-regressions (see the Statistical methods section). Secondary analyses were performed examining any association between the rate of incident cancer and the following variables: baseline LDL-C, age, BMI, sex, and the proportion of subjects who smoked or had diabetes. All the variables that showed a significant univariate association with incident cancer were used to adjust the meta-regression of incident cancer risk and baseline-HDL-C in a multivariate model. The above analyses were all repeated using on-treatment HDL-C in place of baseline HDL-C. Statistical methods. In the main analyses, we assumed that incident cancer rates were normally distributed. We used randomeffects meta-regressions to evaluate the association between incident cancer and baseline HDL-C levels or the other variables of interest, as described previously (12) . We estimated multivariate associations controlling for each of the predictor variables that showed a significant univariate association with incident cancer. We fitted a single regression line to the pooled data of both intervention and control cohorts indexed by a variable indicating cohort type (intervention vs. control). To determine whether the association of HDL-C with cancer differed between the intervention and control arms, we tested the significance of the interaction term of cohort type with baseline HDL-C level. We repeated this analysis for treatment type (statin, fibrate, other intervention or control) to determine whether the association of HDL-C and cancer was significantly modified by treatment type. Continuous variables were compared using the Student t test for independent or paired samples as appropriate. To ensure that our findings were not sensitive to the assumption of a normal distribution of cancer rates, these analyses were repeated, assuming that incident cancer rates follow a Poisson distribution. A p value Ͻ0.05 was considered statistically significant. All analyses were performed with STATA version 9.2 (StataCorp, College Station, Texas).
Results
Eligible trials. Our search yielded 2,300 citations that were screened at the abstract level. A total of 2,250 abstracts were excluded (1,458 with follow-up of Ͻ1,000 person-years, 295 were not lipid intervention studies, and 497 were not RCTs), resulting in 50 full-text articles retrieved for detailed evaluation. Of these, 26 were eventually excluded (20 had Ͻ1,000 person-years of follow-up, 5 did not report cancer incidence [13] [14] [15] [16] [17] , and 1 did not report baseline HDL-C [18] ). Hence, a total of 24 lipid intervention RCTs were included in the main analysis (28 pharmacologic intervention arms and 23 control arms) ( Among all the eligible RCTs, there was a wide range of baseline and on-treatment lipid parameters, with comparable baseline levels in the intervention versus control arms and favorable on-treatment changes in the intervention arms ( Table 1) In univariate random-effects meta-regression analysis, there was a significant inverse relationship between baseline HDL-C level and the rate of incident cancer, such that every 10-mg/dl increment in HDL-C was associated with a 28% (95% confidence interval [CI]: 5% to 45%) relatively lower cancer rate (p ϭ 0.018) (Fig. 1) . The significant inverse association between baseline HDL-C and incident cancer did not differ between the intervention and the control arms (p ϭ 0.95) and was not modified by the type of intervention used (p ϭ 0.726).
SECONDARY ANALYSIS.
When evaluating the other independent variables in the study, there was a significant inverse relationship between baseline LDL-C level and the rate of incident cancer, such that every 10-mg/dl decrement in LDL-C was associated with a 15% (95% CI: 12% to 18%) relatively higher cancer rate (p Ͻ 0.001) (Fig. 2) . In addition, there was a significant and direct relationship between both age and BMI and the rate of incident cancer, such that every 5-year increment in age was associated with a 33% (95% CI: 22% to 45%) relatively higher cancer rate and every 1-kg/m 2 increment in BMI was associated with a 21% (95% CI: 8% to 35%) relatively higher cancer rate (p Ͻ 0.001 and p ϭ 0.001, respectively) (Figs. 3 and 4) . Additionally, sex, the proportion of smokers, and the proportion of patients with diabetes mellitus were significantly associated with incident cancer (p Ͻ 0.01 for all univariate associations). Multivariate meta-regressions. Multivariate randomeffects meta-regression analyses were conducted for baseline HDL-C and incident cancer, controlling for the variables that had significant independent associations with incident cancer in the univariate regression models. After adjusting for baseline LDL-C, age, BMI, diabetes, sex, and smoking status, the significant inverse relationship between baseline HDL-C and rate of incident cancer persisted, such that for every 10-mg/dl increase in HDL-C, there was a 36% (95% CI: 24% to 47%; p Ͻ 0.001) relatively lower rate of incident cancer. In the multivariate model including all relevant variables in addition to HDL-C, LDL-C and sex (percentage of males) continued to have a significant inverse relationship with the rate of incident cancer (p ϭ 0.02 and p ϭ 0.007, respectively), and age continued to have a significant direct relationship with rate of incident cancer (p Ͻ 0.001). In this multivariable model, however, the direct relationship between smoking status and rate of incident cancer approached significance, but failed to achieve it (p ϭ 0.06), and the relationships between both Figure 1 Baseline Levels of HDL-C (mg/dl) and Rate of Incident Cancer per 1,000 Person-Years
The size of each circle represents the relative size (i.e., the weight of the arm) of each trial arm for the lipid intervention arm (black) and the control arm (red).
The solid black line is the combined weighted regression line for all trial arms included in the analysis. p ϭ 0.018. HDL-C ϭ high-density lipoprotein cholesterol.
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BMI and diabetes status with incident cancer rate were no longer statistically significant (p ϭ 0.71 and p ϭ 0.78, respectively). All findings were unchanged when the analyses were repeated using on-treatment instead of baseline HDL-C levels or with Poisson meta-regressions (data not shown).
Discussion
The current analysis demonstrates a significant inverse association between baseline HDL-C levels and the risk of developing cancer in large RCTs of lipid-altering therapy. Importantly, this relationship persisted after controlling for potentially confounding variables, including baseline levels of LDL-C, age, BMI, and smoking status. The present study is the most comprehensive assessment of the relationship between HDL-C and risk of cancer to date. This study builds on the few previous nested casecontrol studies of HDL-C and risk of cancer. Studies from the breast cancer literature provide mixed results. Moorman et al. (8) , in an analysis of 95,000 women from the Kaiser Figure 2 Baseline Levels of LDL-C (mg/dl) and Rate of Incident Cancer per 1,000 Person-Years
The solid black line is the combined weighted regression line for all trial arms included in the analysis. p Ͻ 0.001. LDL-C ϭ low-density lipoprotein cholesterol. (10) suggested that low levels of serum HDL-C are independently associated with increased breast cancer risk in postmenopausal females. Additionally, a recent analysis of the ATBC (Alpha-Tocopherol Beta-Carotene Cancer Prevention) study, examining 29,093 Finnish male smokers, identified a significant inverse relationship between HDL-C levels and the risk of incident cancer. They found that this significant inverse association, largely attributed to cancers of the lung, prostate, liver, and hematopoietic system, persisted after exclusion of cases diagnosed during the first 12 years of follow-up (11) . These previous analyses are limited by sex or cancer type studied, whereas the current study included a mixed population and reported a broad variety of cancers.
As with all association studies, the present study should not be interpreted as implying a causal relationship between low HDL-C levels and cancer risk. However, it is interesting to consider potential biological mechanisms for the observed inverse association between HDL-C and incident cancer risk. The primary mechanism by which HDL-C exerts its atheroprotective effects is via reverse cholesterol transport, but HDL-C has also been shown to have other beneficial effects via its anti-inflammatory and antioxidant properties (7, (43) (44) (45) (46) (47) (48) (49) (50) (51) . Cancer is well-known to be a proinflammatory state, in which inflammatory cells actively participate in the neoplastic process, allowing tumor cell proliferation, survival, and migration (52) (53) (54) . Therefore, it is plausible that HDL-C, by mechanisms that are not yet known, may influence some of the proinflammatory mediators involved in carcinogenesis. Further work will need to be done to elucidate these potential mechanisms.
As a secondary analysis, we examined the other potential variables associated with cancer risk in our dataset. We confirmed our previous report that LDL-C levels are inversely associated with the risk of incident cancer in a similar database (2) . Additionally, the current analysis further supports the well-established association of age and risk of cancer. Furthermore, we demonstrated that in univariate analyses, there was an association between BMI and cancer; however, this relationship was no longer significant after adjusting for HDL-C. The univariate association between BMI and incident cancer reported here is consistent with a recent meta-analysis of prospective observational studies by Renehan et al. (55) , although they did not adjust for HDL-C. Study limitations. Our findings are limited by the use of trial-level data. It is possible that the relationship of HDL-C and cancer could reflect differences in study design that relate to HDL-C at the population level, thus confounding our observed association between HDL-C levels and cancer. Access to individual patient data would allow a more robust analysis. Furthermore, the process for the identification of cancers was not specifically reported, nor was it uniform across all RCTs, and, thus, an effect of differences in the definitions of cancers could not be excluded. Also, many of the recent, large-scale lipidlowering RCTs did not report newly diagnosed cancer (13) (14) (15) (16) (17) , and thus data from these trials could not be The size of each circle represents the relative size (i.e., the weight of the arm) of each trial arm for the lipid intervention arm (black) and the control arm (red).
The solid black line is the combined weighted regression line for all trial arms included in the analysis. p ϭ 0.001. BMI ϭ body mass index.
included. Although the possibility of reverse causality could not be addressed in the current analysis because we did not have access to the individual patient data and could not determine the exact time of cancer diagnosis, it seems unlikely that cancer-associated reductions in HDL-C levels in the small subgroup of these cohorts in which cancer actually developed would significantly affect the mean baseline levels for the large cohort overall. Finally, given the median follow-up time of 5 years, we may not have been able to fully appreciate whether the inverse relationship between HDL-C and incident cancer risk is altered over longer periods of follow-up.
Conclusions
Overall, the current epidemiologic data demonstrate an inverse relationship between serum total cholesterol levels and rate of incident cancer. We recently showed in a meta-analysis that there is a strong inverse relationship between LDL-C and the rate of incident cancer. The current study, based on a systematic analysis, is the first to report a strong and significant inverse relationship between baseline HDL-C and the rate of incident cancer. These findings underscore the importance of reporting cancer rates in future lipid intervention trials and further support the importance of basic scientific research to determine potential underlying mechanisms that might mediate these associations.
